ATRC - AtriCure surges on FDA approval for EPi-Sense System for atrial fibrillation

AtriCure ([[ATRC]] +11.5%) is trading sharply higher today following its announcement of the FDA approval granted for EPi-Sense System to treat patients with long-standing persistent atrial fibrillation (Afib).Affecting an estimated 33M people worldwide, Afib raises the risk of stroke and is linked to an increased risk of mortality. It is also estimated that nearly 45% of patients have long-standing persistent Afib. The endocardial ablation alone is not considered for them due to less-than-optimal outcomes.“The longstanding persistent Afib population represents over three million patients in the United States alone or nearly half of all diagnosed Afib patients,” said Michael Carrel CEO of AtriCure highlighting the potential expansion of the addressable market following the approval.In the CONVERGE trial that evaluated the hybrid AF therapy against endocardial catheter ablation alone, there was a 29% absolute difference in efficacy at 12-months (78% relative improvement).

For further details see:

AtriCure surges on FDA approval for EPi-Sense System for atrial fibrillation